Korsana Biosciences, Inc. (KRSA)
NASDAQ: KRSA · Real-Time Price · USD
31.11
-0.06 (-0.19%)
Nov 10, 2026, 4:00 PM EST - Market closed
Korsana Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
KRSA-028 is designed as a monthly subQ, pyroglutamate-targeting amyloid shuttle, with preclinical design choices aimed at retaining plaque clearance while reducing safety risks. Healthy-volunteer data are targeted for mid-2027, with patient proof-of-concept by late 2027 or Q1 2028.
-
KRSA-028 combines a brain shuttle, modified effector function and subcutaneous dosing, with the goal of improving convenience and safety while retaining plaque clearance. CTA is planned by end-2026, with SAD data expected mid-2027.
-
The all-stock merger pairs a ~$380 million private placement with KRSA-028 development, with cash runway expected into 2029. The program targets key clinical readouts in 2027, subject to merger approval and completion.